Tag: ENTR60144

Browse exclusive Tags!

Entrada Therapeutics Receives UK Authorization for Phase 1 Clinical Trial of Duchenne Medication – Promising Potential for Exon 44 Skipping Treatment, United Kingdom (UK)

Entrada Therapeutics receives UK authorization for Phase 1 trial targeting Duchenne muscular dystrophy - a major milestone in intracellular therapy development.

Popular

Subscribe

spot_imgspot_img